Omeros Corporation (OMER)
| Bid | 6.7 |
| Market Cap | 422.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -156.81M |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -2.32 |
| Forward PE | -13.65 |
| Analyst | Hold |
| Ask | 7.92 |
| Volume | 297,846 |
| Avg. Volume (20D) | 620,445 |
| Open | 7.30 |
| Previous Close | 7.30 |
| Day's Range | 7.10 - 7.48 |
| 52-Week Range | 3.00 - 13.60 |
| Beta | 2.35 |
About OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell tr...
Analyst Forecast
According to 4 analyst ratings, the average rating for OMER stock is "Hold." The 12-month stock price forecast is $22.5, which is an increase of 208.43% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost UsOmeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical an...
2 months ago · businesswire.com
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMASEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros' first-in-class monoclonal...